Literature DB >> 8645250

Decreased ET(B) receptor expression in human metastatic melanoma cells.

K Kikuchi1, H Nakagawa, T Kadono, T Etoh, H R Byers, M C Mihm, K Tamaki.   

Abstract

In this study, we examined the endothelin (ET) receptor subtype involved in mitogenic signaling in human primary and metastatic melanoma cell lines. In a reverse transcriptase-polymerase chain reaction (RT-PCR) study, ET(B) mRNA expression in metastatic melanoma cells was decreased from that of primary melanoma. Only RPM-EP, a primary recurrent melanoma cell line, showed strong ET(A) mRNA expression. ET-1 and ET-3 stimulated DNA synthesis of primary and recurrent cutaneous melanoma cells in serum-deprived cultures. The growth response to ET-1 in metastatic melanoma cells was decreased from that in primary melanoma cells. [125I]-IRL-1620 binding to PM-WK, a primary melanoma cell line, was significantly blocked by excessive amounts of unlabeled BQ-788. [125I]-IRL-1620 binding to metastatic melanoma cells was significantly decreased from that of primary melanoma cells. From these results, we conclude that the mitogenic effects of ET in human primary melanoma are mainly mediated through ET(B) receptors and that down-regulation of ET(B) receptors causes the decreased growth response of ET-1 in metastatic melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645250     DOI: 10.1006/bbrc.1996.0303

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

2.  An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo.

Authors:  R Lahav; G Heffner; P H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

4.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

5.  Expression of endothelin system in neuroblastic tumors: close association of endothelin-1 and endothelin B receptor expression with differentiation of tumor cells.

Authors:  Nobuo Hoshi; Takashi Sugino; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2009-06-18       Impact factor: 2.309

Review 6.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

7.  Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  Pain       Date:  2010-03-04       Impact factor: 7.926

Review 8.  Endothelin-1: a multifunctional molecule in cancer.

Authors:  K Grant; M Loizidou; I Taylor
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

9.  Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor.

Authors:  Jennifer P Montgomery; Paul H Patterson
Journal:  BMC Cancer       Date:  2008-11-28       Impact factor: 4.430

10.  Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma.

Authors:  Y F Zhang; S Jeffery; S A Burchill; P A Berry; J C Kaski; N D Carter
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.